Latest news with #deuruxolitinib
Time of India
14 hours ago
- Business
- Time of India
Sun Pharma shares in focus after $200 million settlement in US drug pricing case
Shares of Sun Pharmaceutical Industries will be in focus on Friday after the company announced that two of its subsidiaries – Sun Pharmaceutical Industries Inc. (SPII) and Taro Pharmaceuticals U.S.A. Inc. (Taro) – have agreed to pay $200 million to settle an antitrust case in the US. The settlement is part of the ongoing In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania. The payment will secure a full release of all claims brought by the End Purchaser Plaintiffs against SPII, Taro, and their current and former affiliates, directors, officers, and employees. Explore courses from Top Institutes in Please select course: Select a Course Category MBA Product Management Data Science Healthcare PGDM others Digital Marketing Design Thinking Project Management Leadership Others Finance Technology healthcare Cybersecurity MCA Data Science Operations Management Degree Artificial Intelligence CXO Public Policy Skills you'll gain: Financial Management Team Leadership & Collaboration Financial Reporting & Analysis Advocacy Strategies for Leadership Duration: 18 Months UMass Global Master of Business Administration (MBA) Starts on May 13, 2024 Get Details Skills you'll gain: Analytical Skills Financial Literacy Leadership and Management Skills Strategic Thinking Duration: 24 Months Vellore Institute of Technology VIT Online MBA Starts on Aug 14, 2024 Get Details The final payout may be adjusted depending on how many class members opt out. Sun Pharma clarified that the settlement does not involve any admission of wrongdoing and is still subject to court approval. In June, Sun Pharma launched LEQSELVI (deuruxolitinib) 8 mg tablets in the US for adults with severe alopecia areata. The rollout follows a settlement and licensing agreement with Incyte Corporation, ending litigation in the District Court of New Jersey. Also Read: IEX crashes nearly 30% after market coupling nod: Technical analysts see no floor yet Live Events As part of that agreement, Sun Pharma obtained a limited, non-exclusive license to certain Incyte patents for non-oncology indications, including alopecia areata. The company will pay an upfront fee and ongoing royalties to Incyte. Other financial terms remain confidential. Sun Pharma share price target According to Trendlyne, the average target price for Sun Pharma is Rs 1,974, implying an upside of 17% from current levels. Out of 36 analysts tracking the stock, the majority maintain a 'Buy' rating. Also Read: Is the IPO market the new gold? 2025 listings outshine Nifty with 4X returns Sun Pharma shares closed 0.56% higher at Rs 1,692.1 on BSE on Thursday, outperforming the 0.66% drop in the Sensex. However, the stock is down 10% year-to-date and has declined 7% in the last six months. ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
&w=3840&q=100)
Business Standard
14-07-2025
- Business
- Business Standard
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp
Sun Pharmaceuticals on Monday announced the launch of hair loss drug Leqselvi (deuruxolitinib) in the United States (US) market for the treatment of alopecia areata, a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The announcement came after the Mumbai-based pharma major inked a settlement pact with US-based Incyte Corporation regarding the hair loss drug. Incyte had earlier accused Sun Pharma of patent infringement. Under the terms of the agreement, the parties will seek dismissal of the pending Leqselvi litigation in the United States District Court for the District of New Jersey. 'Incyte has also granted Sun a limited and non-exclusive licence to US patent numbers 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-haematology-oncology indications including alopecia areata, in the US,' the company said in a regulatory filing on the exchanges. The Mumbai-based pharma major will also pay Incyte an undisclosed upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and licence. Deuruxolitinib is expected to go off-patent in the financial year 2025–26 (FY26). The launch adds Leqselvi to Sun Pharma's innovative therapies portfolio, which saw sales of $1,216 million in FY25, according to Sun Pharma's investor presentation for the year. According to a Reuters report, Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun Pharma's key US market. Commenting on the launch, Sun Pharma America CEO Richard Ascroft said the launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community,' he added. The announcement was made post market hours. On Monday, Sun Pharma's share rose marginally by 0.57 per cent, ending the day's trade at ₹1,682.05 apiece on the Bombay Stock Exchange (BSE).
Business Standard
14-07-2025
- Health
- Business Standard
Sun Pharmaceutical Industries launches LEQSELVI (deuruxolitinib) 8 mg tablets in United States
Used in treatment of severe alopecia areataSun Pharmaceutical Industries announced LEQSELVI (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the U.S. LEQSELVI is indicated for the treatment of adults with severe alopecia launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them, said Richard Ascroft, CEO, Sun Pharma North America. As a company committed to launching new therapeutic options which address the unmet needs of patients, adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community. Powered by Capital Market - Live News
